Drugs that contain Omadacycline Tosylate

1. List of Nuzyra drug patents

NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2023

(a month from now)

US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(5 months from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(7 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

NUZYRA family patents

54

United States

22

Japan

17

European Union

14

China

13

Australia

10

Korea, Republic of

9

Taiwan, Province of China

9

Canada

7

Brazil

6

Denmark

6

Mexico

6

Croatia

6

Spain

EA

6

EA

5

Russia

5

Slovenia

5

Portugal

4

South Africa

4

Hungary

4

Singapore

4

Poland

3

Hong Kong

3

Lithuania

3

Cyprus

3

New Zealand

2

Israel

2

Austria

2

Morocco

2

Philippines

2

Colombia

2

Argentina

2

Czech Republic

2

Chile

2

Ecuador

2

Tunisia

1

Turkey

1

Norway

1

Germany

1

Malaysia

1

Ukraine

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic